ZyVersa Therapeutics, Inc. ZVSA
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.25M | 472.60K | 1.74M | 1.63M | 1.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.30M | 551.90K | 2.10M | 2.04M | 2.14M |
| Operating Income | -1.30M | -551.90K | -2.10M | -2.04M | -2.14M |
| Income Before Tax | -1.79M | -678.60K | -20.66M | -2.21M | -2.26M |
| Income Tax Expenses | -- | 0.00 | -851.70K | -- | -- |
| Earnings from Continuing Operations | -1.79M | -678.60K | -19.81M | -2.21M | -2.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.79M | -678.60K | -19.81M | -2.21M | -2.26M |
| EBIT | -1.30M | -551.90K | -2.10M | -2.04M | -2.14M |
| EBITDA | -- | -550.10K | -2.10M | -2.04M | -2.14M |
| EPS Basic | -0.22 | -0.08 | -2.56 | -0.46 | -0.73 |
| Normalized Basic EPS | -0.11 | -0.07 | -0.16 | -0.29 | -0.45 |
| EPS Diluted | -0.22 | -0.08 | -2.56 | -0.46 | -0.73 |
| Normalized Diluted EPS | -0.11 | -0.07 | -0.16 | -0.29 | -0.45 |
| Average Basic Shares Outstanding | 8.10M | 8.14M | 7.74M | 4.81M | 3.11M |
| Average Diluted Shares Outstanding | 8.10M | 8.14M | 7.74M | 4.81M | 3.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |